Additionally, Rag2–/–Il2rg–/– mice receiving CD3-depleted human primary AML blasts and donor Tc from HLA-mismatched healthy donors and treated with sabatolimab showed improved survival (Figure 7, D and E). This evidence concerns the gene RAG2 and acute myeloid leukemia.